Secukinumab 2‐weekly vs. 4‐weekly dosing in patients with plaque‐type psoriasis: results from the randomized GAIN study*
| Autor: | Ulrich Mrowietz, Kristian Reich, J Früh, Michael Sticherling, Christian Sieder, T. Bachhuber, Andreas Körber |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Medizin Dermatology Antibodies Monoclonal Humanized Severity of Illness Index law.invention 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Double-Blind Method Randomized controlled trial law Psoriasis Area and Severity Index Statistical significance Internal medicine Clinical endpoint medicine Humans Psoriasis Dosing business.industry Dermatology Life Quality Index Confidence interval Treatment Outcome Quality of Life Secukinumab business |
| Zdroj: | British Journal of Dermatology. 184:849-856 |
| ISSN: | 1365-2133 0007-0963 |
| DOI: | 10.1111/bjd.19398 |
| Popis: | BACKGROUND Secukinumab is a fully human monoclonal antibody that selectively neutralizes interleukin-17A and shows long-lasting efficacy and safety in plaque psoriasis. More evidence is required to optimize secukinumab dosing according to clinical response. OBJECTIVES GAIN compared the efficacy and safety of secukinumab 300 mg every 2 weeks (q2w) with 300 mg every 4 weeks (q4w) in patients achieving ≥ 75% improvement in Psoriasis Area and Severity Index (PASI 75) but not PASI 90 after 16 weeks. METHODS In total, 772 patients with moderate-to-severe plaque psoriasis received secukinumab 300 mg subcutaneously at baseline and weeks 1, 2, 3 and 4, then q4w until week 16. At week 16, patients with PASI ≥ 75 to PASI |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text